Lifeboat Foundation

In a recent study published in Molecular Psychiatry, researchers explored the effects of a small humanin-like peptide 2 (SHLP2) variant on mitochondrial function.

Mitochondria are implicated in Parkinson’s disease (PD) pathogenesis. Mitochondrial-derived peptides (MDPs) are microproteins encoded from small open reading frames (sORFs) in the mitochondrial DNA (mtDNA). SHLP2 is an MDP with an essential role in multiple cellular processes, and it improves mitochondrial metabolism by increasing biogenesis and respiration and reducing oxidation.

Recent studies link mitochondrial single nucleotide polymorphisms (mtSNPs) within coding regions of MDPs to age-related deficits. For instance, m.2706 A G, an mtSNP in humanin, predicts reduced circulating levels of humanin and worse cognitive decline. Moreover, another mtSNP, m.2158 T C, is associated with reduced PD risk, albeit the underlying mechanisms are unknown.

A study of around 500,000 medical records suggested that severe viral infections like encephalitis and pneumonia increase the risk of neurodegenerative diseases like Parkinson’s and Alzheimer’s.

Recent studies by Zampaloni et al. and Pahil et al. published in the journal Nature describe a novel method of inhibiting the growth of Gram-negative bacteria such as Acinetobacter using antibiotics consisting of macrocyclic peptides that target the bacterial protein bridge machinery that transports lipopolysaccharides from the cytoplasm to the outer membrane.

The amphipathic lipopolysaccharides in the outer leaflet of the asymmetric outer membrane bilayer of Gram-negative bacteria block antibiotic entry, making the treatment of bacterial infections involving Gram-negative bacteria difficult. Furthermore, the development of antibiotic resistance in bacteria, especially Gram-negative bacteria such as Acinetobacter baumannii, is a rapidly increasing global health concern since antibiotic-resistant bacterial infections are becoming increasingly common among hospitalized and critically ill patients.

The lipopolysaccharide is synthesized inside the bacterial cell in the inner membrane, transported across the cell membrane, and assembled in the outer leaflet. The transportation of lipopolysaccharides occurs with the help of LptB₂FGC, a subcomplex in the inner membrane that enlists adenosine triphosphate (ATP) hydrolysis and a protein bridge to extract lipopolysaccharides from the inner membrane and transport it to the outer membrane. Targeting this transportation complex could effectively inhibit the lipopolysaccharide biosynthesis, making the Gram-negative bacteria susceptible to antibacterial activity.

Study evaluates the impact of hybrid immunity on SARS-CoV-2 antibody levels in Canadian adults, revealing that hybrid immunity, combining vaccination and recovery from infection, significantly reduces COVID-19 morbidity and mortality.

Scientists say they have developed a new type of antibiotic to treat bacteria that is resistant to most current antibiotics and kills a large percentage of people with an invasive infection.

The bacteria, Acinetobacter baumannii, can cause serious infections in the lungs, urinary tract and blood, according to the US Centers for Disease Control and Prevention. It’s resistant to a class of broad-spectrum antibiotics called carbapenems.

Carbapenem-resistant Acinetobacter baumannii, also known as CRAB, was at the top of the World Health Organization’s list of antibiotic-resistant “priority pathogens” in 2017. In the United States, the bacteria caused an estimated 8,500 infections in hospitalized patients and 700 deaths that year, according to the most recent data from the CDC.

Another advantage of fragmentomics is that it requires much less blood than other liquid biopsy tests, she added.

The fragmentomics approach is also appealing because it requires only a blood draw, Dr. Greten noted, which is typically faster, easier to get, and less expensive than an ultrasound.

Fragmentomics is a next-generation liquid biopsy approach, said Dr. Velculescu. And it can potentially be used to detect other kinds of cancer, in addition to those the team has already studied, he added.

Researchers are honing in on ways to halt the progression of MS and maybe even prevent it altogether:

From promising stem cell therapies to EBV vaccines, researchers are closer than ever to finding a cure for MS.

This post is also available in: עברית (Hebrew)

A research team from UNIST has made a discovery that might revolutionize cancer treatment as we know it-new cell-engaging nano-drones that were designed to target and eliminate cancer cells selectively.

These tiny bots are called NK cell-engaging nano-drones (NKeNDs), and their success lies in their ability to engage natural killer (NK) cells, the body’s frontline defenders against cancer. Using NK cells in cancer treatment is not new, but what sets these nanodrones apart is their precision. They are engineered to zero in on cancer cells almost like guided missiles.

🧬 💉 🔬 https://www.news-medical.net/news/20240103/EZH2-inhibitors-s…tment.aspx Type1Diabetes # EZH2Inhibitors # BetaCellRegener…

Study explores the potential of EZH2 inhibitors GSK126 and Tazemetostat in stimulating β-cell regeneration from pancreatic ductal progenitor cells, offering a novel therapeutic approach for Type 1 Diabetes.